INBX
Inhibrx Biosciences, Inc.
Next earnings Aug 11, 2026 · consensus $-2.44 EPS
Last earnings -1.5% on 2026-05-14
$94.81
▼ -0.52%$94.81▲ +535.03%
over 1Y
L $14.43EODHDH $141.84
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.5%
1W-0.5%
1M-8.0%
3M+62.4%
YTD+26.3%
1Y+535.0%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Revenue grew 550.0% YoY; but unprofitable (net margin -10773.5%).
Inhibrx Biosciences, Inc. shows $1.30M in FY2025 revenue (+550.0% YoY), a -10773.5% net margin, and -1752.2% ROE.
Sources: SEC EDGAR (CIK 0002007919, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 7:06:47 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.